Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20100268307 A1
Publication typeApplication
Application numberUS 12/827,700
Publication dateOct 21, 2010
Priority dateApr 8, 2002
Also published asUS7756583, US8818514, US20060142801, US20140012258, US20150018821, WO2007086965A2, WO2007086965A3
Publication number12827700, 827700, US 2010/0268307 A1, US 2010/268307 A1, US 20100268307 A1, US 20100268307A1, US 2010268307 A1, US 2010268307A1, US-A1-20100268307, US-A1-2010268307, US2010/0268307A1, US2010/268307A1, US20100268307 A1, US20100268307A1, US2010268307 A1, US2010268307A1
InventorsDenise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai
Original AssigneeArdian,Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Methods for intravascularly-induced neuromodulation
US 20100268307 A1
Abstract
Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, e.g., with the impedance-altering element deployed into contact with the vessel wall at a treatment site within the patient's vasculature, a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element. In a preferred embodiment, the impedance-altering element comprises an inflatable balloon configured to locally increase impedance within a patient's vasculature. The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function.
Images(7)
Previous page
Next page
Claims(17)
1-14. (canceled)
15. A method for intravascularly-induced neuromodulation, the method comprising:
positioning a pair of bipolar electrodes within a patient's vasculature, the electrodes being spaced less than about 20 mm apart;
increasing impedance within the vasculature between the bipolar electrodes; and
delivering a pulsed electric field across the bipolar electrodes.
16. The method of claim 15, wherein positioning a pair of bipolar electrodes within a patient's vasculature further comprises positioning the pair of bipolar electrodes within the patient's renal artery.
17. The method of claim 15, wherein positioning a pair of bipolar electrodes within a patient's vasculature further comprises positioning an intravascular catheter having the bipolar electrodes within the patient's vasculature.
18. The method of claim 17, wherein positioning an intravascular catheter having the bipolar electrodes further comprises positioning an intravascular catheter having an impedance-altering element positioned between the bipolar electrodes.
19. The method of claim 18, wherein locally increasing impedance further comprises locally increasing impedance with the impedance-altering element.
20. The method of claim 19, wherein locally increasing impedance with the impedance-altering element further comprises occluding blood flow in the vasculature with the impedance-altering element.
21. The method of claim 20, wherein occluding blood flow in the vasculature with the impedance-altering element further comprises inflating a balloon impedance-altering element.
22. The method of claim 15, wherein locally increasing impedance further comprises directing the pulsed electric field across a wall of the patient's vasculature between the bipolar electrodes.
23. The method of claim 15, wherein delivering a pulsed electric field further comprises modulating a neural fiber that contributes to renal function.
24. The method of claim 23, wherein modulating a neural fiber that contributes to renal function further comprises inducing an effect in the neural fiber chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine upregulation alteration, and combinations thereof.
25. The method of claim 15 further comprising substantially centering the bipolar electrodes within the patient's vasculature prior to delivering the pulsed electric field.
26. The method of claim 19, wherein locally increasing impedance with the impedance-altering element further comprises centering the bipolar electrodes within the patient's vasculature.
27. The method of claim 15 further comprising monitoring electroporation in tissue exposed to the pulsed electric field.
28. The method of claim 19, wherein locally increasing impedance with the impedance-altering element further comprises expanding an insulative covering into contact with a wall of the vasculature via a mechanical activation member.
29. The apparatus of claim 1, wherein at least one of the pair of bipolar electrodes comprises a wound coil.
30. A method for intravascularly-induced neuromodulation, the method comprising:
positioning a pair of bipolar electrodes within a patient's vasculature, the electrodes spaced less than about 20 mm apart;
occluding blood flow within the patient's vasculature between the bipolar electrodes; and
delivering a pulsed electric field across the bipolar electrodes.
Description
    INCORPORATION BY REFERENCE
  • [0001]
    All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
  • TECHNICAL FIELD
  • [0002]
    The present invention relates to methods and apparatus for neuromodulation. More particularly, the present invention relates to methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field.
  • BACKGROUND
  • [0003]
    Congestive Heart Failure (“CHF”) is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes impaired, which results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidneys and circulatory system.
  • [0004]
    It is believed that progressively decreasing perfusion of the kidneys is a principal non-cardiac cause perpetuating the downward spiral of CHF. Moreover, the fluid overload and associated clinical symptoms resulting from these physiologic changes result in additional hospital admissions, poor quality of life and additional costs to the health care system.
  • [0005]
    In addition to their role in the progression of CHF, the kidneys play a significant role in the progression of Chronic Renal Failure (“CRF”), End-Stage Renal Disease (“ESRD”), hypertension (pathologically high blood pressure) and other cardio-renal diseases. The functions of the kidneys can be summarized under three broad categories: filtering blood and excreting waste products generated by the body's metabolism; regulating salt, water, electrolyte and acid-base balance; and secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of waste toxins in the blood and body. These conditions result from reduced renal function or renal failure (kidney failure) and are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as fluids are retained and blood toxins accumulate due to the poorly functioning kidneys.
  • [0006]
    It has been established in animal models that the heart failure condition results in abnormally high sympathetic activation of the kidneys. An increase in renal sympathetic nerve activity leads to vasoconstriction of blood vessels supplying the kidneys, decreased renal blood flow, decreased removal of water and sodium from the body, and increased renin secretion. Reduction of sympathetic renal nerve activity, e.g., via denervation, may reverse these processes.
  • [0007]
    Applicants have previously described methods and apparatus for treating renal disorders by applying a pulsed electric field to neural fibers that contribute to renal function. See, for example, co-pending U.S. patent applications Ser. No. 11/129,765, filed on May 13, 2005, and Ser. No. 11/189,563, filed on Jul. 25, 2005, both of which are incorporated herein by reference in their entireties. A pulsed electric field (PEF) may initiate renal neuromodulation, e.g., denervation, for example, via irreversible electroporation or via electrofusion. The PEF may be delivered from apparatus positioned intravascularly, extravascularly, transvascularly or a combination thereof. As used herein, electrofusion comprises fusion of neighboring cells induced by exposure to an electric field. Contact between target neighboring cells for the purposes of electrofusion may be achieved in a variety of ways, including, for example, via dielectrophoresis. In tissue, the target cells may already be in contact, facilitating electrofusion.
  • [0008]
    As used herein, electroporation and electropermeabilization are methods of manipulating the cell membrane or intracellular apparatus. For example, the porosity of a cell membrane may be increased by inducing a sufficient voltage across the cell membrane through, e.g., short, high-voltage pulses. The extent of porosity in the cell membrane (e.g., size and number of pores) and the duration of effect (e.g., temporary or permanent) are a function of multiple variables, such as field strength, pulse width, duty cycle, electric field orientation, cell type or size and other parameters.
  • [0009]
    Cell membrane pores will generally close spontaneously upon termination of relatively lower strength electric fields or relatively shorter pulse widths (herein defined as “reversible electroporation”). However, each cell or cell type has a critical threshold above which pores do not close such that pore formation is no longer reversible; this result is defined as “irreversible electroporation,” “irreversible breakdown” or “irreversible damage.” At this point, the cell membrane ruptures and/or irreversible chemical imbalances caused by the high porosity occur. Such high porosity can be the result of a single large hole and/or a plurality of smaller holes.
  • [0010]
    In some patients, when a PEF sufficient to initiate irreversible electroporation is applied to renal nerves and/or other neural fibers that contribute to renal neural functions, applicants believe that denervation induced by the PEF would result in increased urine output, decreased plasma renin levels, decreased tissue (e.g., kidney) and/or urine catecholamines (e.g., norepinephrine), increased urinary sodium excretion, and/or controlled blood pressure. Such responses would prevent or treat CHF, hypertension, renal system diseases, and other renal or cardio-renal anomalies. PEF systems could be used to modulate efferent or afferent nerve signals, as well as combinations of efferent and afferent nerve signals.
  • [0011]
    A potential challenge of using intravascular PEF systems for treating renal disorders is to selectively electroporate target cells without affecting other cells. For example, it may be desirable to irreversibly electroporate renal nerve cells that travel along or in proximity to renal vasculature, but it may not be desirable to damage the smooth muscle cells of which the vasculature is composed. As a result, an overly aggressive course of PEF therapy may persistently injure the renal vasculature, but an overly conservative course of PEF therapy may not achieve the desired renal neuromodulation.
  • [0012]
    Applicants have previously described methods and apparatus for monitoring tissue impedance or conductivity to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and/or its degree of irreversibility. See, for example, Applicant's co-pending United States patent application Ser. No. 11/233,814, filed Sep. 23, 2005, incorporated by reference as set forth above. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, tissue impedance and conductivity should approximate baseline levels upon cessation of the pulsed electric field. However, if electroporation is irreversible, impedance and conductivity changes should persist after terminating the pulsed electric field. Thus, monitoring the impedance or conductivity of target and/or non-target tissue may be utilized to determine the onset of electroporation and to determine the type or extent of electroporation. Furthermore, monitoring data may be used in one or more manual or automatic feedback loops to control the electroporation.
  • [0013]
    Even when monitoring techniques are utilized, the applied energy or voltage from an intravascular PEF system necessary to establish an electric field of sufficient magnitude to modulate target neural fibers that contribute to renal function may be of a magnitude that causes persistent damage to non-target tissue, such as smooth muscle cells of the vessel wall. Thus, a desired treatment outcome, e.g., renal denervation, may not be achievable with some intravascular PEF systems in certain patients without concomitantly inducing persistent damage to the non-target tissue. It therefore would be desirable to provide methods and apparatus for reducing the required magnitude of applied voltage delivered from an intravascular PEF system necessary to achieve desired neuromodulation in target tissue.
  • SUMMARY
  • [0014]
    The present invention provides methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field (“PEF”). In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes as well as a separation distance between the first and second electrodes may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element. For example, the impedance-altering element can be deployed to contact the vessel wall at a treatment site within the patient's vasculature to locally increase the impedance within a vessel. In a preferred embodiment, the impedance-altering element comprises an inflatable balloon configured to locally increase impedance within a patient's vasculature. The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function.
  • [0015]
    Pulsed electric field parameters may be altered and combined in any combination, as desired. Such parameters can include, but are not limited to, voltage, field strength, pulse width, pulse duration, the shape of the pulse, the number of pulses and/or the interval between pulses (e.g., duty cycle), etc. Suitable field strengths include, for example, strengths of up to about 10,000 V/cm. Suitable pulse widths include, for example, widths of up to about 1 second. Suitable shapes of the pulse waveform include, for example, AC waveforms, sinusoidal waves, cosine waves, combinations of sine and cosine waves, DC waveforms, DC-shifted AC waveforms, RF waveforms, square waves, trapezoidal waves, exponentially-decaying waves, combinations thereof, etc. Suitable numbers of pulses include, for example, at least one pulse. Suitable pulse intervals include, for example, intervals less than about 10 seconds. These parameters are provided for the sake of illustration and should in no way be considered limiting.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    Several embodiments of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:
  • [0017]
    FIG. 1 is a schematic view illustrating human renal anatomy.
  • [0018]
    FIG. 2 is a schematic detail view showing the location of the renal nerves relative to the renal artery.
  • [0019]
    FIGS. 3A and 3B are schematic side- and end-views, respectively, illustrating orienting of an electric field for selectively affecting renal nerves.
  • [0020]
    FIG. 4 is a schematic view illustrating an exemplary intravascular method and apparatus for renal neuromodulation.
  • [0021]
    FIG. 5 is a schematic view illustrating an intravascular method and apparatus of the present invention.
  • [0022]
    FIG. 6 is a schematic view illustrating an alternative intravascular method and apparatus of the present invention.
  • [0023]
    FIGS. 7A-7D are schematic cross-sectional views illustrating Finite Element Analysis modeling of spatial distributions of field strength for various intravascular PEF systems upon application of a constant magnitude applied voltage across bipolar electrodes of the PEF systems while the electrodes are positioned within a patient's renal artery.
  • [0024]
    FIG. 8 is a graph illustrating modeling estimates of induced field strength along the renal artery/fat interface with the PEF systems of FIG. 7.
  • DETAILED DESCRIPTION A. Overview
  • [0025]
    The present invention relates to methods and apparatus for neuromodulation, e.g., denervation. More particularly, the present invention relates to methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element.
  • [0026]
    The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function and may exploit any suitable electrical signal or field parameters, e.g., any electric field that will achieve the desired neuromodulation (e.g., electroporative effect). To better understand the structures of devices of the present invention and the methods of using such devices for renal neuromodulation and monitoring, it is instructive to examine the renal anatomy in humans.
  • B. Selected Embodiments of Methods for Neuromodulation
  • [0027]
    With reference now to FIG. 1, the human renal anatomy includes kidneys K that are supplied with oxygenated blood by renal arteries RA, which are connected to the heart by the abdominal aorta AA. Deoxygenated blood flows from the kidneys to the heart via renal veins RV and the inferior vena cava IVC. FIG. 2 illustrates a portion of the renal anatomy in greater detail. More specifically, the renal anatomy also includes renal nerves RN extending longitudinally along the lengthwise dimension L of renal artery RA generally within the adventitia of the artery. The renal artery RA has smooth muscle cells SMC that surround the arterial circumference and spiral around the angular axis θ of the artery. The smooth muscle cells of the renal artery accordingly have a lengthwise or longer dimension extending transverse (i.e., non-parallel) to the lengthwise dimension of the renal artery. The misalignment of the lengthwise dimensions of the renal nerves and the smooth muscle cells is defined as “cellular misalignment.”
  • [0028]
    Referring to FIG. 3, the cellular misalignment of the renal nerves and the smooth muscle cells may be exploited to selectively affect renal nerve cells with reduced effect on smooth muscle cells. More specifically, because larger cells require a lower electric field strength to exceed the cell membrane irreversibility threshold voltage or energy for irreversible electroporation, several embodiments of electrodes of the present invention are configured to align at least a portion of an electric field generated by the electrodes with or near the longer dimensions of the cells to be affected. In specific embodiments, the device has electrodes configured to create an electrical field aligned with or near the lengthwise dimension L of the renal artery RA to affect renal nerves RN. By aligning an electric field so that the field preferentially aligns with the lengthwise aspect of the cell rather than the diametric or radial aspect of the cell, lower field strengths may be used to affect target neural cells, e.g., to necrose or fuse the target cells, to induce apoptosis, to alter gene expression, to change cytokine upregulation, etc. This is expected to reduce total energy delivered to the system and to mitigate effects on non-target cells in the electric field.
  • [0029]
    Similarly, the lengthwise or longer dimensions of tissues overlying or underlying the target nerve are orthogonal or otherwise off-axis (e.g., transverse) with respect to the longer dimensions of the nerve cells. Thus, in addition to aligning the PEF with the lengthwise or longer dimensions of the target cells, the PEF may propagate along the lateral or shorter dimensions of the non-target cells (i.e., such that the PEF propagates at least partially out of alignment with non-target smooth muscle cells SMC). Therefore, as seen in FIG. 3, applying a PEF with propagation lines Li generally aligned with the longitudinal dimension L of the renal artery RA is expected to preferentially cause electroporation, electrofusion, denervation or other neuromodulation in cells of the target renal nerves RN without unduly affecting the non-target arterial smooth muscle cells SMC. The pulsed electric field may propagate in a single plane along the longitudinal axis of the renal artery, or may propagate in the longitudinal direction along any angular segment θ through a range of 0-360.
  • [0030]
    A PEF system placed within and/or at least partially across the wall of the renal artery may propagate an electric field having a longitudinal portion that is aligned to run with the longitudinal dimension of the artery in the region of the renal nerves RN and the smooth muscle cell SMC of the vessel wall so that the wall of the artery remains at least substantially intact while the outer nerve cells are destroyed, fused or otherwise affected. Monitoring elements may be utilized to assess an extent of, e.g., electroporation, induced in renal nerves and/or in smooth muscle cells, as well as to adjust PEF parameters to achieve a desired effect.
  • C. Exemplary Embodiments of Systems and Additional Methods for Neuromodulation
  • [0031]
    With reference to FIG. 4, an embodiment of an intravascular PEF system and method is described. The system is configured for temporary intravascular placement. Furthermore, the system is configured to deliver a pulsed electric field to neural fibers for neuromodulation, e.g., to deliver the pulsed electric field to neural fibers that contribute to renal function in order to achieve renal neuromodulation. Intravascular pulsed electric field apparatus 100 comprises catheter 102 having a pair of bipolar electrodes 104 positioned along the shaft of the catheter. The electrodes are electrically connected to pulsed electric field generator 50 located external to the patient. The generator may be utilized with any embodiment of the present invention for delivery of a PEF with desired field parameters. It should be understood that PEF-delivery electrodes of embodiments described hereinafter may be electrically connected to the generator, even though the generator is not explicitly shown or described with each embodiment. The electrodes may, for example, be fabricated from wound coils of wire. When utilizing relatively long electrodes, wound coils allow the catheter to maintain a desired degree of flexibility.
  • [0032]
    In use, catheter 102 may, for example, be delivered to renal artery RA as shown, or may be delivered to a renal vein or to any other vessel in proximity to neural tissue contributing to renal function, for example, through a guide catheter. Once positioned within the patient's vasculature, a pulsed electric field may be generated by the PEF generator 50, transferred through catheter 102 to electrodes 104, and delivered via the electrodes 104 across the wall of the vasculature. The PEF therapy modulates the activity along neural fibers, for example, along neural fibers that contribute to renal function, e.g., denervates the neural fibers. This may be achieved, for example, via irreversible electroporation, electrofusion, necrosis and/or inducement of apoptosis in the nerve cells, alteration of gene expression, changes in cytokine upregulation, etc. In many applications, including that shown in FIG. 4, the electrodes are arranged so that the pulsed electric field is aligned with the longitudinal dimension of the renal artery to facilitate modulation of renal nerves with limited effect on non-target smooth muscle cells or other cells.
  • [0033]
    It is expected that PEF therapy will alleviate clinical symptoms of CHF, hypertension, renal disease and/or other cardio-renal diseases for a period of months, potentially up to six months or more. This time period might be sufficient to allow the body to heal; for example, this period might reduce the risk of CHF onset after an acute myocardial infarction, thereby alleviating a need for subsequent re-treatment. Alternatively, as symptoms reoccur, or at regularly scheduled intervals, the patient might return to the physician for a repeat therapy.
  • [0034]
    In order to denervate target neural fibers, apparatus 100 must generate an electric field of sufficient strength or magnitude across the fibers to induce such denervation. Depending upon the arrangement and positioning of electrodes 104 and catheter 102, as well as the physiology of the patient, the applied voltage necessary to achieve a field strength of sufficient magnitude at the neural fibers might also be of sufficient magnitude to induce undesirable persistent injury in non-target tissue, such as smooth muscle cells and/or the vessel wall. It therefore would be desirable to provide apparatus and methods that reduce the necessary applied voltage for intravascular renal denervation via PEF therapy, as compared to the applied voltage required when utilizing apparatus 100.
  • [0035]
    Referring now to FIG. 5, an embodiment of an intravascular PEF system of the present invention is described. This embodiment includes an apparatus 200 comprising a catheter 202 having impedance-altering element 204, such as an inflatable balloon, an expandable cage (e.g., a polymer-coated expandable wire cage) or some other expandable element. Several embodiments of the impedance altering element 204 are configured to center electrodes 206 within a vessel. In a preferred embodiment, impedance-altering element 204 is configured to locally increase impedance within a patient's vasculature. In a further preferred embodiment, impedance-altering element 204 comprises an inflatable balloon, as shown in FIG. 5.
  • [0036]
    PEF-delivery electrodes 206 a and 206 b are positioned along the shaft of catheter 202 with known separation distance D; and optional radiopaque markers 208 are positioned along the shaft of the catheter in the region of impedance-altering element 204. The radiopaque markers 208 can be spaced apart from each other along a balloon-type impedance-altering element by known separation distance d. The electrodes 206 a-b, for example, can be arranged such that the electrode 206 a is near a proximal end of element 204 and the electrode 206 b is near a distal end of the element 204. Electrodes 206 are electrically coupled to pulse generator 50 (see FIG. 4), which is positioned external to the patient, for delivery of PEF therapy. Radiopaque markers additionally or alternatively may be located along the shaft of catheter 202 outside of element 204, as illustrated by radiopaque markets 208′. As yet another alternative or addition, electrodes 206 may be fabricated from a radiopaque material, such as platinum, and utilized as radiopaque markers.
  • [0037]
    Apparatus 200 may further comprise optional monitoring electrodes 210, illustratively also with known separation distance d. Applicants have previously described the use of such monitoring electrodes to monitor tissue impedance or conductivity for determining the effects of pulsed electric field therapy, e.g., for determining an extent of electroporation and/or its degree of irreversibility. See, for example, Applicant's co-pending U.S. patent application Ser. No. 11/233,814, filed Sep. 23, 2005, which is incorporated herein by reference as set forth above. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, tissue impedance and conductivity should approximate baseline levels upon cessation of the pulsed electric field. However, if electroporation is irreversible, impedance and conductivity changes should persist after termination of the pulsed electric field. Thus, monitoring of the impedance or conductivity of target and/or non-target tissue via electrodes 210 may be utilized to determine the onset of electroporation and/or to determine the type or extent of electroporation. Furthermore, monitoring data may be used in one or more manual or automatic feedback loops to control the electroporation.
  • [0038]
    Regardless of whether the effects of PEF therapy are monitored, the magnitude of voltage applied across electrodes 206 in order to establish an electric field of sufficient magnitude to modulate target neural fibers that contribute to renal function also might be of a magnitude that causes persistent damage to non-target tissue, such as smooth muscle cells of the vessel wall. Thus, a desired treatment outcome, e.g., renal denervation, might not be achievable in certain patients without concomitantly inducing persistent damage to the non-target tissue.
  • [0039]
    In accordance with the principles of the present invention, impedance-altering element 204 may reduce the magnitude of voltage applied across electrodes 206 that is required to modulate the target neural fibers. In some patients, this reduction in magnitude might lower the applied voltage below a threshold level that would cause the undesirable persistent damage to the non-target tissue. Element 204 may achieve this reduction in applied voltage magnitude, for example, by locally increasing impedance within the renal vasculature. Element 204 additionally or alternatively may facilitate use of a common applied voltage across a wider range of vessel sizes.
  • [0040]
    In embodiments where the impedance-altering element 204 comprises an inflatable balloon configured to temporarily occlude blood flow during delivery of PEF therapy across electrodes 206, the occluding balloon may serve as an electrical insulator that locally increases electrical impedance during PEF delivery. This impedance increase may direct an electric field delivered across electrodes 206, e.g., may direct the electric field into or across the vessel wall for modulation of target neural fibers. The impedance-altering element 204 electrically insulates a portion of the vessel in a manner that may reduce the magnitude of applied voltage or other parameters of the pulsed electric field necessary to achieve a desired field strength at the target fibers compared to apparatus 100 of FIG. 4 that does not comprise an impedance-altering element. The desired field strength, for example, may have a magnitude sufficient to denervate the target fibers via electroporation. As discussed, this reduction may moderate persistent damage to the non-target tissue. Furthermore, by substantially centering electrodes 206 within the vessel before delivery of PEF therapy, element 204 may further reduce a potential of persistent damage to the non-target tissue of the vessel wall, etc., and/or may facilitate delivery of a more concentrically uniform electric field to the target neural fibers surrounding the renal artery. In addition, or as an alternative, to the use of balloon element 204 to achieve a desired insulation or impedance increase within a patient's vasculature between electrodes 206 during delivery of PEF therapy, the impedance change may be achieved via an insulative covering, e.g., via a polymeric tube or sleeve with closed ends, positioned about a mechanical activation member. The mechanical activation member may be configured to expand the insulative covering into, e.g., circumferential sealing contact with the vessel wall. The mechanical activation member may, for example, comprise an expandable cage. Additional methods and apparatus in accordance with the present invention for achieving the desired impedance change will be apparent to those of skill in the art.
  • [0041]
    With reference now to FIG. 6, an alternative embodiment of apparatus 200 is described. In FIG. 5, impedance-altering element 204 illustratively comprises a semi-compliant balloon that contacts renal artery RA over a length of the artery. In FIG. 6, element 204′ illustratively comprises a substantially non-compliant balloon that contacts the renal artery more focally, e.g., substantially tangentially. Balloon element 204′ of FIG. 6 may have a shorter length than balloon element 204 of FIG. 5, thereby facilitating a shorter separation distance D between PEF-delivery electrodes 206.
  • [0042]
    Finite Element Analysis (“FEA”) modeling of induced electric field strengths from various embodiments of intravascular PEF systems has been conducted to guide the design of preferred intravascular PEF system embodiments that reduce the required applied voltage needed to achieve a desired field strength at target tissue. Modeled variables of the intravascular PEF system designs included use (or lack thereof) of an element configured to locally increase impedance within a patient's vasculature (e.g., a balloon element), the physical design of the impedance-altering element, electrode size (not shown) and electrode spacing (not shown). Varying vessel diameter also was modeled.
  • [0043]
    With reference to FIGS. 7 and 8, the FEA modeling results for four exemplary intravascular PEF systems are provided. Each of the four systems was modeled with a constant applied voltage across the electrodes (e.g., 360V), a constant electrode size (e.g., 6 mm), and a constant electrode separation distance (e.g., 10 mm) within a vessel of constant diameter (e.g., 3.5 mm). These models facilitate study of the effect of the design of the impedance-altering element on induced field strength at target tissue. In FIGS. 7 and 8, the PEF electrodes illustratively are centered with the vessel. The impedance-altering element preferably facilitates centering of the electrodes within the vessel.
  • [0044]
    As seen in FIG. 7A, the first PEF system embodiment comprises a variation of apparatus 100 of FIG. 4 that does not comprise an impedance-altering element or that comprises an undeployed impedance-altering element, such as a deflated balloon element. As seen in FIG. 7B, the second embodiment comprises a variation of apparatus 200 of FIG. 5 comprising a 5 mm-long balloon element configured to alter impedance within a patient's vasculature, illustratively a semi-compliant balloon. In FIG. 7C, the third embodiment comprises a variation of apparatus 200 of FIG. 6 wherein balloon element 204′ is 4 mm long, illustratively non-compliant, and makes only tangential contact with the wall of the renal artery RA. In FIG. 7D, the fourth embodiment comprises another variation of apparatus 200 wherein the balloon element 204″ comprises a disc that occludes the renal artery RA over a very short length and makes substantially tangential wall contact.
  • [0045]
    The four embodiments each comprise a pair of bipolar PEF-delivery electrodes (electrodes 104 in FIG. 7A and electrodes 206 in FIGS. 7B-7D) with a constant separation distance D between each of the electrodes e.g., 10 mm), and a constant electrode length L (e.g., 6 mm). Similar modeling was conducted with a separation distance of 20 mm between the electrodes (not shown), and it was determined that a separation distance of less than about 20 mm is desirable in order to significantly alter the requisite magnitude of applied voltage needed with an inflated balloon to achieve a desired field strength magnitude along target neural tissue. Use of a balloon element when the electrode spacing was about 20 mm or greater showed little difference in required applied voltage between when a balloon was, and was not, used.
  • [0046]
    Electrodes 206 illustratively comprise 6 mm electrodes. Modeling also was conducted with 3 mm electrodes (not shown), and it was determined that the required applied voltage for a given field strength at target tissue generally increases as electrode length decreases. Thus, it generally is desirable to have longer electrodes, for example, electrodes preferably longer than about 1 mm, even more preferably longer than about 2 mm.
  • [0047]
    FIG. 8 provides a graph illustrating modeling estimates of induced field strength in the vicinity of target neural fibers along the renal artery RA/fat F interface I when 360V are applied across modeled bipolar electrodes of the modeled PEF system embodiments of FIG. 7. FIGS. 7 and 8 illustrate that, for the modeled PEF system designs, use of an impedance-altering element such as a balloon directs the electrical field across the wall of the renal artery. Furthermore, the peak field strength induced in the vicinity of the target neural fibers, i.e., at interface I, is increased. Thus, a lower applied voltage may be required to obtain a desired peak electric field strength at interface I when an impedance-altering element is utilized, as compared to when no impedance-altering element is provided or when the impedance-altering element is not deployed (e.g., when a balloon element is not inflated).
  • [0048]
    The modeled systems of FIGS. 7 and 8 illustrate that the contact length between the impedance-altering element and the vessel wall does not substantially alter the peak electric field strength at the interface, so long as some wall contact exists. Furthermore, shorter contact lengths, e.g., contact lengths achieved with balloon elements having lengths of less than about 5 mm, do not substantially alter the peak electric field strength. Additional FEA models (not shown) illustrate that, for the 10 mm spacing of the bipolar electrodes and a given applied voltage, use of an impedance-altering element substantially reduces changes in peak electric field strength associated with changes in vessel diameter, as compared to PEF systems without, or with undeployed, impedance-altering elements, suggesting that a substantially constant applied voltage may be used to achieve a desired electric field strength over a variety of vessel sizes when an impedance-altering element is used. This is in contrast to PEF system embodiments lacking impedance-altering elements; such embodiments might require increasing applied voltages with increasing vessel diameter in order to achieve a given desired peak electric field strength. The range of vessel sizes over which an impedance-altering PEF system may apply a substantially constant voltage to achieve a substantially similar peak field strength at the interface may, for example, vary between about 3 mm and 9 mm.
  • [0049]
    Although preferred illustrative variations of the present invention are described above, it will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the invention. For example, although the variations primarily have been described for use in combination with pulsed electric fields, it should be understood that any other electric field may be delivered as desired. It is intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5300068 *Apr 21, 1992Apr 5, 1994St. Jude Medical, Inc.Electrosurgical apparatus
US5688266 *Oct 3, 1995Nov 18, 1997Ep Technologies, Inc.Electrode and associated systems using thermally insulated temperature sensing elements
US5893885 *Nov 1, 1996Apr 13, 1999Cordis Webster, Inc.Multi-electrode ablation catheter
US6251109 *Jan 20, 1999Jun 26, 2001Daig CorporationProcess and device for the treatment of atrial arrhythmia
US6292695 *Jun 17, 1999Sep 18, 2001Wilton W. Webster, Jr.Method and apparatus for transvascular treatment of tachycardia and fibrillation
US6314325 *Jun 18, 1999Nov 6, 2001William R. FitzNerve hyperpolarization method and apparatus for pain relief
US6845267 *Aug 30, 2001Jan 18, 2005Advanced Bionics CorporationSystems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
US6978174 *Jul 28, 2004Dec 20, 2005Ardian, Inc.Methods and devices for renal nerve blocking
US7162303 *Apr 8, 2003Jan 9, 2007Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US7617005 *Aug 14, 2006Nov 10, 2009Ardian, Inc.Methods and apparatus for thermally-induced renal neuromodulation
US7620451 *Feb 27, 2006Nov 17, 2009Ardian, Inc.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US7647115 *Jun 3, 2005Jan 12, 2010Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US7653438 *Jan 26, 2010Ardian, Inc.Methods and apparatus for renal neuromodulation
US7717948 *Aug 16, 2007May 18, 2010Ardian, Inc.Methods and apparatus for thermally-induced renal neuromodulation
US7756583 *Nov 4, 2005Jul 13, 2010Ardian, Inc.Methods and apparatus for intravascularly-induced neuromodulation
US20050228460 *Jun 3, 2005Oct 13, 2005Levin Howard RRenal nerve stimulation method and apparatus for treatment of patients
US20050234523 *Jun 3, 2005Oct 20, 2005Levin Howard RRenal nerve stimulation method and apparatus for treatment of patients
US20060025821 *May 20, 2005Feb 2, 2006Mark GelfandMethods and devices for renal nerve blocking
US20060041277 *Jul 25, 2005Feb 23, 2006Mark DeemMethods and apparatus for renal neuromodulation
US20060206150 *Mar 6, 2006Sep 14, 2006Ardian, Inc.Methods and apparatus for treating acute myocardial infarction
US20060212076 *Mar 6, 2006Sep 21, 2006Ardian, Inc.Methods and apparatus for treating end-stage renal disease
US20060235474 *Jun 12, 2006Oct 19, 2006Ardian, Inc.Methods and apparatus for multi-vessel renal neuromodulation
US20060265014 *Mar 6, 2006Nov 23, 2006Ardian, Inc.Methods and apparatus for bilateral renal neuromodulation
US20060265015 *Apr 13, 2006Nov 23, 2006Ardian, Inc.Methods and apparatus for monopolar renal neuromodulation
US20060271111 *Mar 6, 2006Nov 30, 2006Ardian, Inc.Methods and apparatus for treating contrast nephropathy
US20060276852 *Mar 6, 2006Dec 7, 2006Ardian, Inc.Methods and apparatus for treating hypertension
US20070066957 *Oct 18, 2005Mar 22, 2007Ardian, Inc.Methods and apparatus for inducing controlled renal neuromodulation
US20070083239 *Sep 23, 2005Apr 12, 2007Denise DemaraisMethods and apparatus for inducing, monitoring and controlling renal neuromodulation
US20070129720 *Nov 14, 2006Jun 7, 2007Ardian, Inc.Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US20070129761 *Nov 14, 2006Jun 7, 2007Ardian, Inc.Methods for treating heart arrhythmia
US20070138575 *Dec 1, 2006Jun 21, 2007Fumitaka AraiSemiconductor memory device and semiconductor device including multilayer gate electrode
US20070173899 *Mar 19, 2007Jul 26, 2007Ardian, Inc.Renal nerve stimulation method for treatment of patients
US20070265687 *Jul 24, 2007Nov 15, 2007Ardian, Inc.Apparatuses for renal neuromodulation
US20080213331 *Apr 8, 2008Sep 4, 2008Ardian, Inc.Methods and devices for renal nerve blocking
US20080255642 *Jun 26, 2008Oct 16, 2008Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20090036948 *Aug 6, 2008Feb 5, 2009Ardian, Inc.Renal nerve stimulation methods for treatment of patients
US20090062873 *Jun 26, 2008Mar 5, 2009Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20090076409 *Jun 28, 2007Mar 19, 2009Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20100010567 *Jan 14, 2010The Foundry, LlcSystems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20100057150 *Nov 11, 2009Mar 4, 2010Ardian, Inc.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20100127952 *Nov 25, 2008May 27, 2010Motorola, Inc.Dual helix, dual pitch antenna for wide frequency bandwidth
US20100137860 *Aug 11, 2009Jun 3, 2010Ardian, Inc.Apparatus for performing a non-continuous circumferential treatment of a body lumen
US20100168731 *Jul 1, 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168739 *Jun 30, 2009Jul 1, 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100174282 *Mar 16, 2010Jul 8, 2010Ardian, Inc.Apparatus for thermal modulation of nerves contributing to renal function
US20100191112 *Apr 5, 2010Jul 29, 2010Ardian, Inc.Ultrasound apparatuses for thermally-induced renal neuromodulation
US20100222851 *May 11, 2010Sep 2, 2010Ardian, Inc.Methods for monitoring renal neuromodulation
US20100222854 *May 11, 2010Sep 2, 2010Ardian, Inc.Apparatuses for inhibiting renal nerve activity via an intra-to-extravascular approach
US20100249773 *Apr 13, 2010Sep 30, 2010Ardian, Inc.Handle assemblies for intravascular treatment devices and associated systems and methods
Non-Patent Citations
Reference
1 *Davalos et al. "Tissue Ablation with Irreversible Electroporation", Annals of Biomedical Engineering , Vol. 33 No.2, February 2005.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8131371Apr 13, 2006Mar 6, 2012Ardian, Inc.Methods and apparatus for monopolar renal neuromodulation
US8131372Mar 19, 2007Mar 6, 2012Ardian, Inc.Renal nerve stimulation method for treatment of patients
US8145316Mar 27, 2012Ardian, Inc.Methods and apparatus for renal neuromodulation
US8145317Mar 6, 2006Mar 27, 2012Ardian, Inc.Methods for renal neuromodulation
US8150518Jun 3, 2005Apr 3, 2012Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US8150519Mar 6, 2006Apr 3, 2012Ardian, Inc.Methods and apparatus for bilateral renal neuromodulation
US8150520Mar 6, 2006Apr 3, 2012Ardian, Inc.Methods for catheter-based renal denervation
US8175711May 8, 2012Ardian, Inc.Methods for treating a condition or disease associated with cardio-renal function
US8347891Nov 14, 2006Jan 8, 2013Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8433423Dec 13, 2010Apr 30, 2013Ardian, Inc.Methods for multi-vessel renal neuromodulation
US8444640May 21, 2013Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8454594Aug 11, 2009Jun 4, 2013Medtronic Ardian Luxembourg S.A.R.L.Apparatus for performing a non-continuous circumferential treatment of a body lumen
US8504147Sep 25, 2009Aug 6, 2013Medtronic Ardian Luxembourg S.A.R.L.Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US8548600Sep 14, 2012Oct 1, 2013Medtronic Ardian Luxembourg S.A.R.L.Apparatuses for renal neuromodulation and associated systems and methods
US8551069Mar 6, 2006Oct 8, 2013Medtronic Adrian Luxembourg S.a.r.l.Methods and apparatus for treating contrast nephropathy
US8568399Mar 7, 2013Oct 29, 2013Metavention, Inc.Methods for thermally-induced hepatic neuromodulation
US8579891Mar 7, 2013Nov 12, 2013Metavention, Inc.Devices for thermally-induced hepatic neuromodulation
US8620423Mar 14, 2011Dec 31, 2013Medtronic Ardian Luxembourg S.A.R.L.Methods for thermal modulation of nerves contributing to renal function
US8626300Mar 11, 2011Jan 7, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for thermally-induced renal neuromodulation
US8652129Aug 21, 2009Feb 18, 2014Medtronic Ardian Luxembourg S.A.R.L.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8676309Jun 28, 2013Mar 18, 2014Medtronic Ardian Luxembourg S.A.R.L.Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US8684998Mar 9, 2012Apr 1, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for inhibiting renal nerve activity
US8721637Jul 12, 2013May 13, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US8728069Oct 23, 2013May 20, 2014Metavention, Inc.Modulation of nerves that innervate the liver
US8728070Oct 23, 2013May 20, 2014Metavention, Inc.Hepatic neuromodulation methods
US8728075Aug 30, 2010May 20, 2014Medtronic Ardian Luxembourg S.A.R.L.Multi-directional deflectable catheter apparatuses, systems, and methods for renal neuromodulation
US8728137Feb 12, 2013May 20, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US8728138Feb 12, 2013May 20, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US8740896Jul 12, 2013Jun 3, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US8758334Nov 1, 2013Jun 24, 2014Metavention, Inc.Hepatic neuromodulation devices
US8768469Aug 6, 2009Jul 1, 2014Enteromedics Inc.Systems for regulation of blood pressure and heart rate
US8768470May 11, 2010Jul 1, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for monitoring renal neuromodulation
US8771252May 20, 2005Jul 8, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and devices for renal nerve blocking
US8774913Nov 14, 2006Jul 8, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for intravasculary-induced neuromodulation
US8774922May 21, 2013Jul 8, 2014Medtronic Ardian Luxembourg S.A.R.L.Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US8777942Oct 22, 2010Jul 15, 2014Medtronic Ardian Luxembourg S.A.R.L.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8784463Feb 12, 2013Jul 22, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US8805545Apr 16, 2013Aug 12, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for multi-vessel renal neuromodulation
US8808345Apr 13, 2010Aug 19, 2014Medtronic Ardian Luxembourg S.A.R.L.Handle assemblies for intravascular treatment devices and associated systems and methods
US8818514Jul 2, 2013Aug 26, 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for intravascularly-induced neuromodulation
US8845629Apr 5, 2010Sep 30, 2014Medtronic Ardian Luxembourg S.A.R.L.Ultrasound apparatuses for thermally-induced renal neuromodulation
US8852163Jun 28, 2013Oct 7, 2014Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods
US8870863May 28, 2010Oct 28, 2014Medtronic Ardian Luxembourg S.A.R.L.Catheter apparatuses, systems, and methods for renal neuromodulation
US8876813Mar 14, 2013Nov 4, 2014St. Jude Medical, Inc.Methods, systems, and apparatus for neural signal detection
US8876815Jun 11, 2014Nov 4, 2014Metavention, Inc.Energy delivery devices for hepatic neuromodulation
US8880185Jun 25, 2013Nov 4, 2014Boston Scientific Scimed, Inc.Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US8880186Apr 11, 2013Nov 4, 2014Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients with chronic heart failure
US8894639May 16, 2014Nov 25, 2014Metavention, Inc.Hepatic artery nerve modulation methods
US8900223Nov 8, 2010Dec 2, 2014Tsunami Medtech, LlcTissue ablation systems and methods of use
US8909316Jun 6, 2011Dec 9, 2014St. Jude Medical, Cardiology Division, Inc.Apparatus and method of assessing transvascular denervation
US8934978Apr 22, 2014Jan 13, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US8934988Mar 16, 2012Jan 13, 2015St. Jude Medical AbAblation stent with meander structure
US8939970Feb 29, 2012Jan 27, 2015Vessix Vascular, Inc.Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US8948865Nov 15, 2013Feb 3, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for treating heart arrhythmia
US8951251Nov 7, 2012Feb 10, 2015Boston Scientific Scimed, Inc.Ostial renal nerve ablation
US8958871Jan 14, 2011Feb 17, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US8974445Jan 7, 2010Mar 10, 2015Recor Medical, Inc.Methods and apparatus for treatment of cardiac valve insufficiency
US8974446Feb 2, 2011Mar 10, 2015St. Jude Medical, Inc.Ultrasound ablation apparatus with discrete staggered ablation zones
US8974451Oct 25, 2011Mar 10, 2015Boston Scientific Scimed, Inc.Renal nerve ablation using conductive fluid jet and RF energy
US8979839Nov 15, 2010Mar 17, 2015St. Jude Medical, Inc.Assembly of staggered ablation elements
US8983595Nov 21, 2013Mar 17, 2015Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients with chronic heart failure
US8986294Feb 4, 2010Mar 24, 2015Medtronic Ardian Luxembourg S.a.rl.Apparatuses for thermally-induced renal neuromodulation
US9005100Dec 14, 2012Apr 14, 2015The Board Of Trustees Of The Leland Stanford Jr. UniversityApparatus and methods for treating pulmonary hypertension
US9005190Nov 8, 2013Apr 14, 2015Metavention, Inc.Treatment of non-alcoholic fatty liver disease
US9005191Nov 8, 2013Apr 14, 2015Metavention, Inc.Neuromodulation methods using balloon catheter
US9011422Sep 25, 2014Apr 21, 2015Metavention, Inc.Hepatic neuromodulation to treat fatty liver conditions
US9023034Nov 22, 2011May 5, 2015Boston Scientific Scimed, Inc.Renal ablation electrode with force-activatable conduction apparatus
US9023037Apr 23, 2013May 5, 2015Medtronic Ardian Luxembourg S.A.R.L.Balloon catheter apparatus for renal neuromodulation
US9028391Apr 4, 2014May 12, 2015The Board Of Trustees Of The Leland Stanford Jr. UniversityApparatus and methods for treating pulmonary hypertension
US9028472Dec 21, 2012May 12, 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9028485Sep 23, 2011May 12, 2015Boston Scientific Scimed, Inc.Self-expanding cooling electrode for renal nerve ablation
US9033969Nov 8, 2013May 19, 2015Metavention, Inc.Nerve modulation to treat diabetes
US9037259Dec 21, 2012May 19, 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9050106Dec 21, 2012Jun 9, 2015Boston Scientific Scimed, Inc.Off-wall electrode device and methods for nerve modulation
US9060761Nov 9, 2011Jun 23, 2015Boston Scientific Scime, Inc.Catheter-focused magnetic field induced renal nerve ablation
US9060784Nov 8, 2013Jun 23, 2015Metavention, Inc.Hepatic denervation systems
US9072527Jul 15, 2013Jul 7, 2015Medtronic Ardian Luxembourg S.A.R.L.Apparatuses and methods for renal neuromodulation
US9072902Dec 21, 2012Jul 7, 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9079000Oct 16, 2012Jul 14, 2015Boston Scientific Scimed, Inc.Integrated crossing balloon catheter
US9084609Jul 18, 2011Jul 21, 2015Boston Scientific Scime, Inc.Spiral balloon catheter for renal nerve ablation
US9089350Nov 9, 2011Jul 28, 2015Boston Scientific Scimed, Inc.Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9089541Nov 8, 2013Jul 28, 2015Metavention, Inc.Gastroduodenal artery neuromodulation
US9089542Sep 25, 2014Jul 28, 2015Metavention, Inc.Hepatic neuromodulation using microwave energy
US9089700Aug 7, 2009Jul 28, 2015Cibiem, Inc.Systems and methods for treating dyspnea, including via electrical afferent signal blocking
US9095711Jun 30, 2014Aug 4, 2015Enteromedics Inc.Systems for regulation of blood pressure and heart rate
US9108040Jun 26, 2014Aug 18, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for multi-vessel renal neuromodulation
US9113929Feb 28, 2013Aug 25, 2015St. Jude Medical, Cardiology Division, Inc.Non-electric field renal denervation electrode
US9113944Nov 19, 2012Aug 25, 2015Tsunami Medtech, LlcMethod for performing lung volume reduction
US9114123Oct 31, 2014Aug 25, 2015Metavention, Inc.Hepatic neuromodulation using fluids or chemical agents
US9114124Dec 26, 2014Aug 25, 2015Metavention, Inc.Modulation of nerves innervating the liver
US9119600Nov 15, 2012Sep 1, 2015Boston Scientific Scimed, Inc.Device and methods for renal nerve modulation monitoring
US9119632Nov 16, 2012Sep 1, 2015Boston Scientific Scimed, Inc.Deflectable renal nerve ablation catheter
US9125661Oct 17, 2013Sep 8, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US9125666Sep 28, 2007Sep 8, 2015Vessix Vascular, Inc.Selectable eccentric remodeling and/or ablation of atherosclerotic material
US9125667Oct 18, 2007Sep 8, 2015Vessix Vascular, Inc.System for inducing desirable temperature effects on body tissue
US9131978Apr 23, 2014Sep 15, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US9131982Mar 14, 2013Sep 15, 2015St. Jude Medical, Cardiology Division, Inc.Mediguide-enabled renal denervation system for ensuring wall contact and mapping lesion locations
US9131983Oct 18, 2013Sep 15, 2015Ablative Solutions, Inc.Methods ablating tissue using a catheter-based injection system
US9138281Sep 23, 2013Sep 22, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets
US9149329Nov 8, 2013Oct 6, 2015Metavention, Inc.Glucose alteration methods
US9155589Jul 22, 2011Oct 13, 2015Boston Scientific Scimed, Inc.Sequential activation RF electrode set for renal nerve ablation
US9161801Dec 30, 2010Oct 20, 2015Tsunami Medtech, LlcMedical system and method of use
US9162046Sep 28, 2012Oct 20, 2015Boston Scientific Scimed, Inc.Deflectable medical devices
US9173696Sep 17, 2013Nov 3, 2015Boston Scientific Scimed, Inc.Self-positioning electrode system and method for renal nerve modulation
US9174050Dec 21, 2012Nov 3, 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9179962Dec 4, 2013Nov 10, 2015Ablative Solutions, Inc.Transvascular methods of treating extravascular tissue
US9179973Mar 15, 2013Nov 10, 2015St. Jude Medical, Cardiology Division, Inc.Feedback systems and methods for renal denervation utilizing balloon catheter
US9179997Mar 6, 2013Nov 10, 2015St. Jude Medical, Cardiology Division, Inc.Thermochromic polyvinyl alcohol based hydrogel artery
US9186198Sep 14, 2012Nov 17, 2015Medtronic Ardian Luxembourg S.A.R.L.Ultrasound apparatuses for thermally-induced renal neuromodulation and associated systems and methods
US9186209Jul 20, 2012Nov 17, 2015Boston Scientific Scimed, Inc.Nerve modulation system having helical guide
US9186210Oct 10, 2012Nov 17, 2015Boston Scientific Scimed, Inc.Medical devices including ablation electrodes
US9186211Jan 25, 2013Nov 17, 2015Boston Scientific Scimed, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9186212Mar 15, 2013Nov 17, 2015St. Jude Medical, Cardiology Division, Inc.Feedback systems and methods utilizing two or more sites along denervation catheter
US9186213May 15, 2014Nov 17, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation
US9192435Nov 22, 2011Nov 24, 2015Boston Scientific Scimed, Inc.Renal denervation catheter with cooled RF electrode
US9192715Mar 21, 2014Nov 24, 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for renal nerve blocking
US9192790Apr 13, 2011Nov 24, 2015Boston Scientific Scimed, Inc.Focused ultrasonic renal denervation
US9204889Sep 12, 2011Dec 8, 2015Tsunami Medtech, LlcMedical instrument and method of use
US9220558Oct 26, 2011Dec 29, 2015Boston Scientific Scimed, Inc.RF renal denervation catheter with multiple independent electrodes
US9220561Jan 19, 2012Dec 29, 2015Boston Scientific Scimed, Inc.Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9237925Aug 2, 2011Jan 19, 2016Ablative Solutions, Inc.Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation
US9254360Jun 30, 2014Feb 9, 2016Ablative Solutions, Inc.Peri-vascular tissue ablation catheter with deflection surface support structures
US9265558Apr 23, 2014Feb 23, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US9265575Nov 8, 2013Feb 23, 2016Metavention, Inc.Balloon catheter neuromodulation systems
US9265969Dec 10, 2012Feb 23, 2016Cardiac Pacemakers, Inc.Methods for modulating cell function
US9277955Apr 11, 2011Mar 8, 2016Vessix Vascular, Inc.Power generating and control apparatus for the treatment of tissue
US9278196Aug 24, 2011Mar 8, 2016Ablative Solutions, Inc.Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
US9283033Jul 1, 2013Mar 15, 2016Cibiem, Inc.Carotid body ablation via directed energy
US9289255Mar 3, 2015Mar 22, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US9297845Mar 4, 2014Mar 29, 2016Boston Scientific Scimed, Inc.Medical devices and methods for treatment of hypertension that utilize impedance compensation
US9301795Nov 20, 2013Apr 5, 2016Ablative Solutions, Inc.Transvascular catheter for extravascular delivery
US9308043Nov 20, 2014Apr 12, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for monopolar renal neuromodulation
US9308044Nov 20, 2014Apr 12, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for therapeutic renal neuromodulation
US9314300Sep 29, 2015Apr 19, 2016St. Jude Medical Cardiology Division, Inc.Feedback systems and methods for renal denervation utilizing balloon catheter
US9314630Nov 20, 2014Apr 19, 2016Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients
US9314644Jun 26, 2008Apr 19, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and systems for thermally-induced renal neuromodulation
US9320561Nov 20, 2014Apr 26, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US9320850Jun 30, 2014Apr 26, 2016Ablative Solutions, Inc.Peri-vascular tissue ablation catheter with unique injection fitting
US9326751Nov 14, 2011May 3, 2016Boston Scientific Scimed, Inc.Catheter guidance of external energy for renal denervation
US9326817Dec 1, 2014May 3, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for treating heart arrhythmia
US9327100Mar 12, 2013May 3, 2016Vessix Vascular, Inc.Selective drug delivery in a lumen
US9327122Feb 2, 2015May 3, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for catheter-based renal neuromodulation
US9345900Jun 26, 2008May 24, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and systems for thermally-induced renal neuromodulation
US9358365Jul 30, 2011Jun 7, 2016Boston Scientific Scimed, Inc.Precision electrode movement control for renal nerve ablation
US9364280Dec 17, 2014Jun 14, 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US9364284Oct 10, 2012Jun 14, 2016Boston Scientific Scimed, Inc.Method of making an off-wall spacer cage
US20060212078 *Mar 6, 2006Sep 21, 2006Ardian, Inc.Methods and apparatus for treating congestive heart failure
US20070265687 *Jul 24, 2007Nov 15, 2007Ardian, Inc.Apparatuses for renal neuromodulation
US20090036948 *Aug 6, 2008Feb 5, 2009Ardian, Inc.Renal nerve stimulation methods for treatment of patients
US20090076409 *Jun 28, 2007Mar 19, 2009Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20100010567 *Jan 14, 2010The Foundry, LlcSystems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20100137860 *Aug 11, 2009Jun 3, 2010Ardian, Inc.Apparatus for performing a non-continuous circumferential treatment of a body lumen
US20100168731 *Jul 1, 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168739 *Jun 30, 2009Jul 1, 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100222851 *May 11, 2010Sep 2, 2010Ardian, Inc.Methods for monitoring renal neuromodulation
US20100222854 *May 11, 2010Sep 2, 2010Ardian, Inc.Apparatuses for inhibiting renal nerve activity via an intra-to-extravascular approach
US20110112400 *May 12, 2011Ardian, Inc.High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation
US20110166499 *Jul 7, 2011Ardian, Inc.Methods and apparatus for inducing controlled renal neuromodulation
US20110200171 *Aug 18, 2011Ardian, Inc.Methods and apparatus for renal neuromodulation via stereotactic radiotherapy
US20110202098 *Aug 18, 2011Ardian, Inc.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
USD747491Oct 23, 2013Jan 12, 2016St. Jude Medical, Cardiology Division, Inc.Ablation generator
Classifications
U.S. Classification607/74, 604/21, 607/116
International ClassificationA61N1/02
Cooperative ClassificationA61B2018/00613, A61B2018/00434, A61B2018/00285, A61B17/12136, A61B2018/00083, A61B18/1492, A61M25/0108, A61N1/37205, A61N1/36182, A61N1/36007, A61N1/327, A61N1/36121, A61M25/10, A61N1/40
European ClassificationA61N1/36Z, A61N1/36, A61N1/32S, A61M25/10
Legal Events
DateCodeEventDescription
Jul 2, 2010ASAssignment
Owner name: ARDIAN, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMARAIS, DENISE;ZADNO, NICOLAS;CLARK, BENJAMIN J.;AND OTHERS;REEL/FRAME:024633/0887
Effective date: 20060222
Jun 3, 2013ASAssignment
Owner name: MEDTRONIC ARDIAN LLC, DELAWARE
Free format text: CHANGE OF NAME;ASSIGNOR:ARDIAN, INC.;REEL/FRAME:030531/0816
Effective date: 20110121
Owner name: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L., LUXEMBOURG
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDTRONIC ARDIAN LLC;REEL/FRAME:030531/0717
Effective date: 20120203